MedTrace Logo

Spermotrend in the Treatment of Male Infertility

NCT00975117 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2011-03-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether the administration of the dietary supplement Spermotrend improves spermatogenesis parameters in subjects with male infertility unrelated to major testicular conditions. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of males with infertility to be recruited and randomized for the study is 86.

Conditions

  • Male Infertility

Interventions

DIETARY_SUPPLEMENT

Placebo

One Placebo tablet (Orally administered) twice a day, for 12 weeks.

DIETARY_SUPPLEMENT

Spermotrend

One Spermotrend tablet (Orally administered) twice a day, for 12 weeks

Sponsors & Collaborators

  • Catalysis SL

    lead INDUSTRY

Principal Investigators

  • Miguel Aguilar Charara, MD · "Ramón González Coro" Gynecologic and Obstetric Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975117 on ClinicalTrials.gov